Research Analysts Offer Predictions for HRMY FY2025 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Harmony Biosciences in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan forecasts that the company will earn $3.71 per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $58.00 price objective on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share.

Harmony Biosciences (NASDAQ:HRMY) last released its earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. The company had revenue of $186.00 million for the quarter, compared to analyst estimates of $184.07 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm’s quarterly revenue was up 16.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.63 EPS.

A number of other equities research analysts have also issued reports on HRMY. Needham & Company LLC reaffirmed a “buy” rating and issued a $52.00 price target on shares of Harmony Biosciences in a research report on Monday, January 13th. Mizuho raised their target price on shares of Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Thursday, October 10th. HC Wainwright reiterated a “buy” rating and set a $75.00 price target on shares of Harmony Biosciences in a report on Thursday, January 16th. Oppenheimer restated an “outperform” rating and issued a $59.00 price objective (up from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Finally, Raymond James reiterated an “outperform” rating and set a $40.00 target price on shares of Harmony Biosciences in a research note on Thursday, October 10th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $55.00.

Harmony Biosciences Stock Down 1.7 %

Shares of NASDAQ HRMY opened at $38.01 on Wednesday. Harmony Biosciences has a 12-month low of $28.14 and a 12-month high of $41.61. The stock has a market cap of $2.17 billion, a P/E ratio of 18.01, a PEG ratio of 0.53 and a beta of 0.78. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The business’s fifty day simple moving average is $34.66 and its 200-day simple moving average is $35.05.

Institutional Trading of Harmony Biosciences

A number of large investors have recently bought and sold shares of the business. GAMMA Investing LLC increased its stake in Harmony Biosciences by 92.6% in the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after purchasing an additional 436 shares during the period. Mendota Financial Group LLC grew its holdings in shares of Harmony Biosciences by 24,125.0% during the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock worth $33,000 after buying an additional 965 shares during the last quarter. CWM LLC increased its position in Harmony Biosciences by 111.7% in the 3rd quarter. CWM LLC now owns 1,469 shares of the company’s stock valued at $59,000 after acquiring an additional 775 shares during the period. Quarry LP purchased a new stake in Harmony Biosciences during the 2nd quarter valued at approximately $62,000. Finally, KBC Group NV lifted its position in Harmony Biosciences by 79.9% during the 4th quarter. KBC Group NV now owns 1,844 shares of the company’s stock worth $63,000 after acquiring an additional 819 shares during the period. Institutional investors and hedge funds own 86.23% of the company’s stock.

Insider Buying and Selling

In related news, insider Jeffrey Dierks sold 10,507 shares of the company’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $37.01, for a total value of $388,864.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jeffrey M. Dayno sold 19,293 shares of Harmony Biosciences stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $40.13, for a total value of $774,228.09. The disclosure for this sale can be found here. Insiders have sold 77,419 shares of company stock worth $3,082,455 in the last ninety days. 30.80% of the stock is owned by corporate insiders.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.